Form 4: Avalo Therapeutics Director Mitchell Chan Granted Stock Options

Avalo Therapeutics, Inc. Director Mitchell Chan was granted 20,100 stock options with an exercise price of $4.47, vesting fully on the first anniversary of the grant date.

Summary

• Mitchell Chan, a Director of Avalo Therapeutics, Inc. (AVTX), was granted stock options.
• The transaction occurred on June 17, 2025.
• He acquired 20,100 stock options.
• The exercise price for these options is $4.47 per share.
• The options expire on June 17, 2035.
• The options vest 100% on the first anniversary of the grant date (June 17, 2026), contingent on his continued service.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's interests with the long-term performance of the company and its shareholders, indicating commitment.

Positives

• The grant of stock options to a director aligns their interests with the long-term performance and shareholder value creation of Avalo Therapeutics, Inc.

Negatives

• No specific negative aspects related to the company's performance or outlook are indicated in this Form 4 filing.

Risks

• The vesting of the stock options is subject to the Eligible Director's continued service on the vesting date, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

This Form 4 filing primarily reports an insider transaction and does not contain forward-looking statements regarding the company's financial performance or strategic outlook, beyond the vesting schedule of the granted options.

Industry Context

The granting of stock options to directors is a common and standard practice across various industries, particularly in biotechnology and pharmaceutical sectors, to incentivize long-term commitment and align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a widely accepted practice within the industry, aligning the director's financial incentives with the company's stock performance. The specific terms (exercise price, vesting schedule) are typical for such grants, though the exact number of options can vary based on company size, compensation philosophy, and individual roles.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's financial interests with the creation of shareholder value, potentially leading to more focused decision-making for long-term growth.

Next Steps

• The stock options will vest on June 17, 2026, subject to Mitchell Chan's continued service as a director.

Key Dates

Recommendation

Keywords

Avalo Therapeutics, AVTX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Mitchell Chan